1. Home
  2. ERO vs BEAM Comparison

ERO vs BEAM Comparison

Compare ERO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ero Copper Corp.

ERO

Ero Copper Corp.

HOLD

Current Price

$25.06

Market Cap

3.2B

Sector

N/A

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$22.17

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERO
BEAM
Founded
2016
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ERO
BEAM
Price
$25.06
$22.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
14
Target Price
$37.50
$52.21
AVG Volume (30 Days)
1.1M
1.9M
Earning Date
03-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
$53.59
N/A
Revenue Next Year
N/A
$39.64
P/E Ratio
$22.61
N/A
Revenue Growth
N/A
33.33
52 Week Low
$9.30
$13.53
52 Week High
$39.80
$36.44

Technical Indicators

Market Signals
Indicator
ERO
BEAM
Relative Strength Index (RSI) 38.13 33.18
Support Level $23.01 $20.23
Resistance Level $26.77 $23.42
Average True Range (ATR) 1.11 1.31
MACD -0.12 -0.29
Stochastic Oscillator 38.24 1.75

Price Performance

Historical Comparison
ERO
BEAM

About ERO Ero Copper Corp.

Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: